Insmed reported $727.89M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Cytokinetics USD 1.2B 338.79M Sep/2025
DBV Technologies USD 8.59M 295K Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.89M 163.33M Dec/2025
Novartis USD 32.02B 615M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025